Dr. Munshi on the Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma


Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Kraft Family Chair, senior physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Patients with relapsed/refractory multiple myeloma have limited treatment options that often do not lead to significant responses, says Munshi.

CAR T-cell therapy has elicited high response rates in this setting for patients who are heavily pretreated, explains Munshi.

Data from the phase 2 KarMMA trial revealed that the CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121) induced a 73.4% overall response rate in patients with relapsed/refractory multiple myeloma. Additionally, topline results from the trial showed a complete response rate of 31.3%.

Although other potential targets are being evaluated in the space, BCMA is a validated target worthy of continued investigation, says Munshi. As such, CAR T-cell therapy is poised to have significant impact on the treatment of patients with multiple myeloma.

<<< 2020 ASCO Virtual Scientific Program

Related Videos
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
© 2024 MJH Life Sciences

All rights reserved.